-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – volixibat potassium
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry volixibat potassium Drug Details Volixibat potassium (SHP-626, LUM-002) is under development for adult cholestasis...
-
Product Insights
Heywood Solar PV Park
Heywood solar PV Park is a 80MW solar PV power project located in Victoria, Australia. It is being developed by AusNet Services Ltd; Countrywide Renewable Energy Pty Ltd. The project is currently in the announced stage. The project is expected to enter commercial operation in 2025. The project is owned by AusNet Services Ltd; Commonwealth Scientific and Industrial Research Organisation; Countrywide Renewable Energy Pty Ltd; Deakin University; Glenelg Shire Council; ITM Power Pty Ltd. Heywood solar PV Park profile includes...
-
Product Insights
Retinopathy of Prematurity Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinopathy Of Prematurity – Drugs In Development, 2022, provides an overview of the Retinopathy Of Prematurity (Ophthalmology) pipeline landscape. Retinopathy of prematurity (ROP) is a disease that affects immature vasculature in the eyes of premature babies. This disorder which usually develops in both eyes is one of the most common causes of visual loss in childhood and can lead to lifelong vision impairment and blindness Risk factors for the development...
-
Sector Analysis
Contract Manufacturing Service Agreements – Rising Manufacturing Opportunities Driven by Pharmaceutical Pipeline Expansion
This report is a brand new publication covering contract service agreements, across a range of different services and manufacturing scales. The number of contract service agreements secured serves as a primary indicator of a CMO's performance. Contract Manufacturing Service Agreements is critical for establishing an understanding of the overall CMO industry, the range of services provided and the features of some of the largest CMOs participating in the industry.
-
Thematic Analysis
Deal-Making Trends in Pharma – Thematic Research
To gain a better understanding of the pharmaceutical deal landscape, this report will dive into three separate deal categories: strategic partnerships, licensing activity, and M&A activity. Furthermore, the categories will be further broken down by four dominating therapeutic themes. These include gene therapy, immuno-oncology, microbiome, and orphan drugs. These themes are among those expected to have the greatest presence in deals made within the pharmaceutical industry, which is indicative of the optimism surrounding their future potential. Please also note that...
-
Sector Analysis
Hemophilia A and B – Global Drug Forecast and Market Analysis to 2028
Hemophilia A and B are rare, genetic, X-linked deficiencies in the blood clotting factors VIII (FVIII) and IX (FIX), respectively. Patients can be categorized as mild, moderate or severe depending on the percentage of circulating FVIII or FIX in their blood. Patients can be treated either on-demand or prophylactically using plasma-derived or recombinant replacement factors, the current standard of care. Although these therapies are effective, they are associated with a great treatment burden. There is a significant unmet need for...
-
Track & Monitor
CMO Scorecard – Outsourcing of NDA Approvals and CMO Performance – 2019 PharmSource Edition
This report is the 9th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs.
-
Sector Analysis
Chronic Kidney Disease-Mineral Bone Disorders (CKD-MBD) – Competitive Landscape to 2027
Chronic Kidney Disease–Mineral Bone Disorders (CKD-MBD) is one of the many complications associated with overall CKD. The systemic disorder is identified from high parathyroid hormone and disrupted K+/Ca2+ levels caused by a decreasing glomerular filtration rate (GFR) due to renal impairment. This report provides an assessment of the pipeline, clinical, and commercial landscape of CKD-MBD. Overall, GlobalData expects minimal changes to overall disease treatment, with exceptions being the launch of the novel NHE3 and novel CASR in the US and...
-
Track & Monitor
PharmSource – M&A in the Contract Manufacturing Industry: Implications and Outlook – 2018 Edition
This report is the 2nd edition of our analysis of Mergers and Acquisitions in the contract manufacturing industry. PharmSource is the most definitive, trustworthy source of strategic insight on this topic in the bio/pharmaceutical realm.